Stock analysis searches answered, part 22 of 43

Docgo inc. bullish and bearish analyst opinions

For “Docgo inc. bullish and bearish analyst opinions”, the matching SEC registrant is DocGo Inc., which trades as DCGO and files under Central Index Key 1822359. EDGAR puts it in the “Services-Health Services” industry code with DE as its state or country of incorporation; its earlier registered name was Motion Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-05, across 412 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-16 by DocGo Inc. (CIK 1822359) — source document:

We are democratizing access with our innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. Our goal is to deliver healthcare at any address and help reshape the traditional healthcare system, driven by our mission to bring high quality, highly accessible care to all. DocGo’s proprietary technology platform, dedicated network of certified health professionals, including virtual care clinicians, and robust fleet of medical response vehicles provide services in all 50 states and the United Kingdom. DocGo’s vertically integrated approach helps elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. We often provide our services in collaboration with leading healthcare organizations via long-term relationships that are intended to provide efficient and strategic capital deployment opportunities that can drive meaningful revenue and create significant growth.

Financial trend for DocGo Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $440.52 million (2022-12-31) to $322.20 million (2025-12-31), a change of -26.9%; net income (loss) went from $34.58 million (2022-12-31) to -$182.40 million (2025-12-31), a change of -627.4%; total assets went from $393.28 million (2022-12-31) to $217.10 million (2025-12-31), a change of -44.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1822359, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures DocGo Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on DocGo Inc. (CIK 1822359) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-17, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 66 8-K or 6-K reports in DocGo Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1822359 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2020-08-28. Insider trades for DocGo Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Dogness (international) corporation bullish and bearish analyst opinions

For “Dogness (international) corporation bullish and bearish analyst opinions”, the matching SEC registrant is Dogness (International) Corp, which trades as DOGZ and files under Central Index Key 1707303. EDGAR puts it in the “Miscellaneous Manufacturing Industries” industry code with Virgin Islands, British as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-20, across 169 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-10-01 by Dogness (International) Corp (CIK 1707303) — source document:

Dogness (International) Corporation (“Dogness”) was incorporated as a British Virgin Islands company limited by shares under the BVI Business Companies Act (As Revised), on July 11, 2016. Dogness has an indefinite term. Dogness was established to operate principally as a holding company. Dogness and its subsidiaries (collectively the “Company”) are principally engaged in the design and manufacture of pet products, including leashes and smart products, and lanyards in China. Most products are exported to the U.S. and Europe and sold to pet stores, including major pet store chains. The share capital of Dogness was US$200,000, divided into 100,000,000 Common Shares of par value US$0.002 each. In connection with the incorporation of Dogness, 15,000,000 Common Shares were issued to Silong Chen, Dogness’ founder and Chief Executive Officer.

Financial trend for Dogness (International) Corp from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $1.70 million (2023-06-30) to $101,455 (2024-06-30), a change of -94.0%; net income (loss) went from -$7.20 million (2023-06-30) to -$27.63 million (2026-06-30), a change of -283.7%; total assets went from $97.87 million (2023-06-30) to $94.12 million (2026-06-30), a change of -3.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1707303, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Dogness (International) Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Dogness (International) Corp (CIK 1707303) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-10-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 59 8-K or 6-K reports in Dogness (International) Corp’s recent EDGAR index, the 4 listed here run from 2026-04-02 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1707303 is on the EDGAR company page; the latest 20-F there is dated 2026-10-01 and the oldest filing in the recent index dates from 2017-05-30. Insider trades for Dogness (International) Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Douyu international holdings limited bullish and bearish analyst opinions

For “Douyu international holdings limited bullish and bearish analyst opinions”, the matching SEC registrant is DouYu International Holdings Ltd, which trades as DOYU and files under Central Index Key 1762417. EDGAR puts it in the “Services-Computer Programming, Data Processing, Etc.” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-09-10, across 148 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-17 by DouYu International Holdings Ltd (CIK 1762417) — source document:

In February 2016, Guangzhou Douyu and Wuhan Douyu entered into an asset and business transfer agreement, pursuant to which Guangzhou Douyu transferred all of its business operations and assets to Wuhan Douyu (the “2016 Wuhan Douyu Restructuring”). In February 2016, Wuhan Douyu, Wuhan Ouyue, the successor of Zhejiang Ouyue, which was acquired by Mr. Shaojie Chen in November 2015, and Mr. Chen entered into a series of contractual arrangements, by which Wuhan Douyu may exert control over Wuhan Ouyue and consolidate Wuhan Ouyue’s financial statements. In May 2018, such contractual arrangements were terminated and replaced by contractual arrangements between Douyu Yule, Wuhan Ouyue and Mr. This entity focuses on entering into business contracts with streamers.

Financial trend for DouYu International Holdings Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 7,108,238,352 CNY (2022-12-31) to 3,818,851,679 CNY (2025-12-31), a change of -46.3%; net income (loss) went from -75,422,408 CNY (2022-12-31) to -29,081,925 CNY (2025-12-31), a change of +61.4%; total assets went from 8,145,366,409 CNY (2022-12-31) to 3,119,951,030 CNY (2025-12-31), a change of -61.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1762417, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures DouYu International Holdings Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on DouYu International Holdings Ltd (CIK 1762417) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 58 8-K or 6-K reports in DouYu International Holdings Ltd’s recent EDGAR index, the 4 listed here run from 2026-03-25 to 2026-08-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1762417 is on the EDGAR company page; the latest 20-F there is dated 2026-04-17 and the oldest filing in the recent index dates from 2019-01-16. Insider trades for DouYu International Holdings Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Dynamix corporation iii forecast and analysis

For “Dynamix corporation iii forecast and analysis”, the matching SEC registrant is Dynamix Corp III, which trades as DNMX, DNMXU, DNMXW and files under Central Index Key 2081125. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-08-14, across 28 filings on record. This is reference material, not trading advice.

The registration statement on Form S-1 (File No. 333-289517) for our initial public offering (the “initial public offering”) was declared effective by the Securities and Exchange Commission (the “SEC”) on October 29, 2025. On October 31, 2025, the Company consummated the initial public offering of 20,125,000, including 2,625,000 units as a result of the underwriters’ full exercise of their overallotment option (the “Units”), at an offering price of $10.00 per Unit. The gross proceeds from the initial public offering were $201,250,000 in the aggregate. Simultaneous with the consummation of the initial public offering and the issuance and sale of the Units, the Company consummated the private placement (the “private placement”) of 6,275,000 private placement warrants at a price of $1.00 per Private Placement Warrant, generating total gross proceeds of $6,275,000.

Analyst ratings, price targets and “bullish” or “bearish” calls on Dynamix Corp III (CIK 2081125) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

Edesa biotech, inc. bullish and bearish analyst opinions

For “Edesa biotech, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Edesa Biotech, Inc., which trades as EDSA and files under Central Index Key 1540159. EDGAR puts it in the “Pharmaceutical Preparations” industry code with British Columbia, Canada as its state or country of incorporation; its earlier registered name was Stellar Biotechnologies, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 748 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-12 by Edesa Biotech, Inc. (CIK 1540159) — source document:

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches.

Financial trend for Edesa Biotech, Inc. from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from -$17.55 million (2022-09-30) to -$7.19 million (2025-09-30), a change of +59.1%; total assets went from $11.58 million (2022-09-30) to $13.53 million (2025-09-30), a change of +16.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1540159, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Edesa Biotech, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Edesa Biotech, Inc. (CIK 1540159) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2025-12-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 230 8-K or 6-K reports in Edesa Biotech, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1540159 is on the EDGAR company page; the latest 10-K there is dated 2025-12-12 and the oldest filing in the recent index dates from 2012-02-03. Insider trades for Edesa Biotech, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Einride ab bullish and bearish analyst opinions

For “Einride ab bullish and bearish analyst opinions”, the matching SEC registrant is Einride AB, which trades as ENRD, ENRDW and files under Central Index Key 2095096. EDGAR puts it in the “Services-Computer Integrated Systems Design” industry code with Sweden as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-09, across 79 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Einride AB (CIK 2095096) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 12 8-K or 6-K reports in Einride AB’s recent EDGAR index, the 4 listed here run from 2026-09-04 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 79 recent EDGAR filings, Einride AB most often filed 425 (28), 3 (14), 6-K (12), 424B3 (6). A selection from 2026-09-04 to 2026-10-01:

The full record for CIK 2095096 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-11-12. Insider trades for Einride AB appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Elan microelectronics corporation bullish and bearish analyst opinions

What this search refers to. Elan Microelectronics Corporation is a Taiwanese chip designer known for touchpad controllers, listed on the Taiwan Stock Exchange; its filings are on MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Elan microelectronics corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Elan microelectronics corporation” appears in 1264+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “elan” (search terms considered: elan, microelectronics, corporation).

In the 100 most relevant full-text hits returned for “Elan microelectronics corporation”, filings range from 2001-12-27 to 2026-10-23. The filers whose documents mention it most often are JNL SERIES TRUST (CIK 0000933691) (19 hits); Thrivent Core Funds (CIK 0001669626) (13 hits); WELLS FARGO MASTER TRUST (CIK 0001087961) (11 hits); ASIA TIGERS FUND INC (CIK 0000912729) (8 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 65 entities whose registered name contains the word “elan”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “elan” 65, “microelectronics” 26, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “elan” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Electromed, inc. bullish and bearish analyst opinions

For “Electromed, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Electromed, Inc., which trades as ELMD and files under Central Index Key 1488917. EDGAR puts it in the “Electromedical & Electrotherapeutic Apparatus” industry code with MN as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEF 14A filed 2026-09-29, across 578 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-08-25 by Electromed, Inc. (CIK 1488917) — source document:

Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System (“SmartVest System”) to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation (“HFCWO”) treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations. We primarily employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes.

Financial trend for Electromed, Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $48.07 million (2023-06-30) to $54.72 million (2024-06-30), a change of +13.8%; net income (loss) went from $3.17 million (2023-06-30) to $11.30 million (2026-06-30), a change of +256.9%; total assets went from $45.81 million (2023-06-30) to $66.27 million (2026-06-30), a change of +44.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1488917, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Electromed, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Electromed, Inc. (CIK 1488917) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-25, and the most recent 10-K annual report was filed 2026-08-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 139 8-K or 6-K reports in Electromed, Inc.’s recent EDGAR index, the 4 listed here run from 2025-12-18 to 2026-08-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1488917 is on the EDGAR company page; the latest 10-K there is dated 2026-08-25 and the oldest filing in the recent index dates from 2010-05-03. Insider trades for Electromed, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Enel américas s.a. bullish and bearish analyst opinions

For “Enel américas s.a. bullish and bearish analyst opinions”, the matching SEC registrant is ENEL AMERICAS S.A., which trades as none listed and files under Central Index Key 912505. EDGAR puts it in the “Electric Services” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was ENERSIS AMERICAS S.A. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2022-11-02, across 655 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2022-04-29 by ENEL AMERICAS S.A. (CIK 912505) — source document:

Operating and Financial Review and Prospects ​ 80 ​ ​ Item 6. Directors, Senior Management and Employees ​ 144 ​ ​ Item 7. Major Shareholders and Related Party Transactions ​ 152 ​ ​ Item 8. Financial Information ​ 154 ​ ​ Item 9. The Offer and Listing ​ 156 ​ ​ Item 10. Additional Information ​ 156 ​ ​ Item 11. Quantitative and Qualitative Disclosures About Market Risk ​ 172 ​ ​ Item 12. Description of Securities Other Than Equity Securities ​ 176 ​ ​ PART II ​ ​ ​ ​ Item 13. Defaults, Dividend Arrearages and Delinquencies ​ 177 ​ ​ Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds ​ 177 ​ ​ Item 15.

Financial trend for ENEL AMERICAS S.A. from annual reports, periods 2018-12-31 to 2021-12-31: revenue went from $11.92 billion (2018-12-31) to $14.54 billion (2021-12-31), a change of +21.9%; net income (loss) went from $1.67 billion (2018-12-31) to $1.13 billion (2021-12-31), a change of -31.9%; total assets went from $27.40 billion (2018-12-31) to $34.96 billion (2021-12-31), a change of +27.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 912505, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures ENEL AMERICAS S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ENEL AMERICAS S.A. (CIK 912505) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2022-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 455 8-K or 6-K reports in ENEL AMERICAS S.A.’s recent EDGAR index, the 4 listed here run from 2022-08-24 to 2022-11-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 912505 is on the EDGAR company page; the latest 20-F there is dated 2022-04-29 and the oldest filing in the recent index dates from 2002-02-04. Insider trades for ENEL AMERICAS S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Energous corporation bullish and bearish analyst opinions

For “Energous corporation bullish and bearish analyst opinions”, the matching SEC registrant is Energous Corp, which trades as WATT and files under Central Index Key 1575793. EDGAR puts it in the “Radio & Tv Broadcasting & Communications Equipment” industry code with DE as its state or country of incorporation; its earlier registered name was DvineWave Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-18, across 810 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Energous Corp (CIK 1575793) — source document:

We have developed scalable, over-the-air Wireless Power Network (“WPN”) technology that integrates advanced semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (“RF”)-based charging for ambient Internet of Things (“IoT”) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. Our WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. These capabilities support applications that require continuous operation without wired power connections or periodic battery replacement. With a patent portfolio exceeding 300 patents, our solutions support both near-field and at-a-distance wireless power transmission and include advanced receiver technology designed for use across multiple device categories.

Financial trend for Energous Corp from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$26.28 million (2022-12-31) to -$9.59 million (2025-12-31), a change of +63.5%; total assets went from $29.75 million (2022-12-31) to $16.74 million (2025-12-31), a change of -43.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1575793, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Energous Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Energous Corp (CIK 1575793) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 130 8-K or 6-K reports in Energous Corp’s recent EDGAR index, the 4 listed here run from 2026-03-25 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1575793 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2013-05-22. Insider trades for Energous Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Enlight renewable energy ltd bullish and bearish analyst opinions

For “Enlight renewable energy ltd bullish and bearish analyst opinions”, the matching SEC registrant is Enlight Renewable Energy Ltd., which trades as ENLT and files under Central Index Key 1922641. EDGAR puts it in the “Electric Services” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13, across 197 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-30 by Enlight Renewable Energy Ltd. (CIK 1922641) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 82 A. Operating Results 89 B. Liquidity and Capital Resources 96 C. Research and Development, Patents and Licenses, Etc. 107 D. Trend Information 107 E. Critical Accounting Estimates 107 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 108 A. Directors and Senior Management 108 B. Compensation 111 C. Board Practices 118 D. Employees 128 E. Share Ownership 129 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 129 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 129 A. Major Shareholders 129 B. Related Party Transactions 132 C. Interests of Experts and Counsel 132 ITEM 8. FINANCIAL INFORMATION 132 A. Consolidated Statements and Other Financial Information 132 B. Significant Changes 133 ITEM 9.

Financial trend for Enlight Renewable Energy Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $192.17 million (2022-12-31) to $488.60 million (2025-12-31), a change of +154.2%; net income (loss) went from $38.11 million (2022-12-31) to $160.70 million (2025-12-31), a change of +321.6%; total assets went from $3.53 billion (2022-12-31) to $8.63 billion (2025-12-31), a change of +144.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1922641, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Enlight Renewable Energy Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Enlight Renewable Energy Ltd. (CIK 1922641) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 85 8-K or 6-K reports in Enlight Renewable Energy Ltd.’s recent EDGAR index, the 4 listed here run from 2026-07-08 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1922641 is on the EDGAR company page; the latest 20-F there is dated 2026-03-30 and the oldest filing in the recent index dates from 2022-07-25. Insider trades for Enlight Renewable Energy Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ensysce biosciences, inc. bullish and bearish analyst opinions

For “Ensysce biosciences, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Ensysce Biosciences, Inc., which trades as ENSC and files under Central Index Key 1716947. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Leisure Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-3 filed 2026-10-23, across 545 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by Ensysce Biosciences, Inc. (CIK 1716947) — source document:

We were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from PharmacoFore, Inc. to Signature Therapeutics Inc. (“ Signature ”). In December 2015, Signature merged with and into Ensysce Biosciences, Inc. (“ Former Ensysce ”). In June 2021, Former Ensysce merged with and into Leisure Acquisition Corporation (“ LACQ ”). As part of the transaction, LACQ changed its name to “Ensysce Biosciences, Inc.” The mailing address of our principal executive office is 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Our corporate telephone number is (858) 263-4196. Our website address is www.ensysce.com. The information disclosed by the foregoing channels could be deemed to be material information.

Financial trend for Ensysce Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.52 million (2022-12-31) to $5.07 million (2025-12-31), a change of +100.8%; total assets went from $5.89 million (2022-12-31) to $7.45 million (2025-12-31), a change of +26.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1716947, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Ensysce Biosciences, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ensysce Biosciences, Inc. (CIK 1716947) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 125 8-K or 6-K reports in Ensysce Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1716947 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2017-10-03. Insider trades for Ensysce Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Evaxion biotech a/s bullish and bearish analyst opinions

For “Evaxion biotech a/s bullish and bearish analyst opinions”, the matching SEC registrant is Evaxion A/S, which trades as EVAX and files under Central Index Key 1828253. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with Denmark as its state or country of incorporation; its earlier registered name was Evaxion Biotech A/S. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-23, across 360 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-05 by Evaxion A/S (CIK 1828253) — source document:

Prior to the transformation, on April 1, 2014, our legal name changed from Novvac ApS to Evaxion Biotech ApS. April 20, 2025, our legal name changed from Evaxion Biotech A/S to Evaxion A/S. We commenced operations in August 2008. Our corporate website address is www.evaxion.ai. We have included our website address as an inactive textual reference only. Our shares (ADSs) are traded on The Nasdaq Capital Market under the symbol “EVAX”. This validated and scalable platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccines for cancer and infectious diseases. We are planning to expand into autoimmune diseases as well. Based upon AI-Immunology™, Evaxion has developed a pipeline of preclinical and clinical R&D-programs, including therapeutic cancer vaccines (both personal and off-the-shelf) and prophylactic vaccines against bacterial and viral diseases with high unmet medical needs.

Financial trend for Evaxion A/S from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2022-12-31) to $7.53 million (2025-12-31); net income (loss) went from -$23.17 million (2022-12-31) to -$7.71 million (2025-12-31), a change of +66.7%; total assets went from $22.02 million (2022-12-31) to $28.41 million (2025-12-31), a change of +29.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1828253, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Evaxion A/S did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Evaxion A/S (CIK 1828253) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 240 8-K or 6-K reports in Evaxion A/S’s recent EDGAR index, the 4 listed here run from 2026-09-14 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1828253 is on the EDGAR company page; the latest 20-F there is dated 2026-03-05 and the oldest filing in the recent index dates from 2020-10-22. Insider trades for Evaxion A/S appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Exozymes, inc. bullish and bearish analyst opinions

For “Exozymes, inc. bullish and bearish analyst opinions”, the matching SEC registrant is EXOZYMES INC., which trades as EXOZ and files under Central Index Key 2010788. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with NV as its state or country of incorporation; its earlier registered name was Invizyne Technologies Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4/A filed 2026-10-21, across 127 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by EXOZYMES INC. (CIK 2010788) — source document:

Chemicals are ubiquitous in modern life - they form the basis of medicines, fuels, plastics, food, and colors, among many other applications that together contribute to our ability to live “the good life” in the modern world. Harvesting chemicals from nature via traditional extraction methods is often inefficient and often requires large amounts of biological material to extract the necessary amounts of the desired chemical compounds. So, despite maybe being sustainable, it is not enough to supply the world’s demand through natural extraction, and it is not as scalable, as cost effective, or as flexible as using petrochemicals from a manufacturing point of view. Since the discovery of oil and the advance of petrochemistry, the world has used petrochemical production methods to produce many desired chemicals—but petrochemical production is often toxic and environmentally damaging and, therefore, unsustainable.

Financial trend for EXOZYMES INC. from annual reports, periods 2023-12-31 to 2025-12-31: revenue was tagged only for 2023-12-31 at $70,069; net income (loss) went from -$2.04 million (2023-12-31) to -$9.16 million (2025-12-31), a change of -349.3%; total assets went from $3.56 million (2023-12-31) to $5.97 million (2025-12-31), a change of +67.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2010788, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures EXOZYMES INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on EXOZYMES INC. (CIK 2010788) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 22 8-K or 6-K reports in EXOZYMES INC.’s recent EDGAR index, the 4 listed here run from 2026-06-26 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2010788 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2024-02-09. Insider trades for EXOZYMES INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Feng chi biotech corp. bullish and bearish analyst opinions

What this search refers to. Feng Chi Biotech Corp. is a Taiwanese company name; Taiwan’s emerging-board and listed companies file on MOPS rather than EDGAR. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Feng chi biotech corp. bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Feng chi biotech corp.”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “feng” (search terms considered: feng, chi, biotech).

Even the shorter phrase “Feng chi biotech” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (feng, chi, biotech) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 145 entities whose registered name contains the word “feng”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “feng” 145, “chi” 204, “biotech” 384. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “feng”: ANG ZHI FENG (CIK 1928131), BAI FENG (CIK 1378534), CHEN FENG MARK (CIK 2143863); containing “chi”: A-CHI-28-FUND, A SERIES OF AX-ABVC-FUNDS, LLC (CIK 1685662), A-CHI-28-PR-FUND, A SERIES OF AX-ABVC-FUNDS, LLC (CIK 1716594), ABRUZZO ELSA CHI (CIK 1336062); containing “biotech”: 2009 BIOTECH VSC, L.P. (CIK 1463664), 2009 BIOTECH VSP, L.P. (CIK 1463663), 2010 BIOTECH VSC, L.P. (CIK 1486163). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “feng” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Ferroglobe plc bullish and bearish analyst opinions

For “Ferroglobe plc bullish and bearish analyst opinions”, the matching SEC registrant is Ferroglobe PLC, which trades as GSM and files under Central Index Key 1639877. EDGAR puts it in the “Metal Mining” industry code with United Kingdom as its state or country of incorporation; its earlier registered name was VeloNewco Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-09, across 297 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-26 by Ferroglobe PLC (CIK 1639877) — source document:

Ferroglobe PLC Ferroglobe PLC, initially named VeloNewco Limited, was incorporated under the U.K. Companies Act 2006 as a private limited liability company in the United Kingdom on February 5, 2015. The Company was a wholly-owned subsidiary of Grupo Villar Mir (“Grupo VM”). On October 16, 2015, VeloNewco Limited re-registered as a public limited company. As a result of the Business Combination, which was completed on December 23, 2015, Ferroglobe Spain Metals and Ferroglobe USA (formerly FerroAtlántica and Globe, respectively) merged through corporate transactions to create Ferroglobe PLC, one of the largest producers worldwide of silicon metal and silicon and manganese-based alloys. To effect the Business Combination, Ferroglobe acquired from Grupo VM all of the issued and outstanding ordinary shares, par value €1,000 per share, of Ferroglobe Spain Metals in exchange for 98,078,161 newly issued Class A Ordinary Shares, nominal value $7.50 per share, of Ferroglobe, after which Ferroglobe Spain Metals became a wholly-owned subsidiary of Ferroglobe.

Financial trend for Ferroglobe PLC from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $443.83 million (2022-12-31) to -$177.11 million (2025-12-31), a change of -139.9%; total assets went from $1.96 billion (2022-12-31) to $1.42 billion (2025-12-31), a change of -27.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1639877, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Ferroglobe PLC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ferroglobe PLC (CIK 1639877) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 166 8-K or 6-K reports in Ferroglobe PLC’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1639877 is on the EDGAR company page; the latest 20-F there is dated 2026-03-26 and the oldest filing in the recent index dates from 2015-05-06. Insider trades for Ferroglobe PLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Firefly ab (publ) bullish and bearish analyst opinions

Read from its name, “Firefly ab (publ)” is a Sweden entity — “AB (publ)” marks a Swedish public limited company (aktiebolag) allowed to offer shares to the public. Its accounts and exchange notices are published through Nasdaq Stockholm / Spotlight announcements and the Swedish FSA (Finansinspektionen) register (www.fi.se); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Firefly ab (publ) bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Firefly ab publ”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “firefly” (search terms considered: firefly).

A broader EDGAR full-text search for the shorter phrase “Firefly ab” finds 15 filing documents; among the top 15, the filers mentioning it most are MILLICOM INTERNATIONAL CELLULAR SA (TIGO, MLCMF) (CIK 0000912958) (7); INDUSTRIFORVALTNINGS AB KINNEVIK (CIK 0000941513) (5); DFA INVESTMENT TRUST CO (CIK 0000896162) (4). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Sweden. Companies there file with Nasdaq Stockholm and Finansinspektionen rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “firefly” is therefore the Sweden regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 42 entities whose registered name contains the word “firefly”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “firefly” 42. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “firefly” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Ftc cintas unifirst

A query pairing the Federal Trade Commission with uniform-rental companies Cintas and UniFirst. Each company named is a separate SEC registrant reporting on its own; filing data as of Oct 25, 2026.

UNIFIRST CORP (UNF; services-personal services, incorporated in MA): its index shows the 8-K of 2026-10-21 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-09-11 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2018-08-25: reported revenue $1.70 billion, bottom line $163.90 million (10-K, 2018-10-22).

CINTAS CORP (CTAS; men's & boys' furnishgs, work clothg, & allied garments, incorporated in WA): its index shows the 8-K of 2026-10-06 covering 8.01 (other events); the 8-K of 2026-09-23 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2019-05-31: reported revenue $6.89 billion, bottom line $884.98 million (10-K, 2019-07-26).

Item 2.02 count (results of operations and financial condition — the item that accompanies an earnings release): UNF 64 (latest 2026-10-21), CTAS 73 (latest 2026-09-23).

The Federal Trade Commission reviews large mergers under the Hart-Scott-Rodino Act, which is why it appears alongside these two names: Cintas has made public offers to acquire UniFirst, and any agreed combination of two of the largest U.S. uniform-rental firms would face antitrust review. Filings about such an approach would show up as 8-K or Schedule 14A documents from either company.

Fulcrum metals plc bullish and bearish analyst opinions

The legal-form ending in “Fulcrum metals plc” is the clue: “plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. A company of that kind reports in the United Kingdom, so the place to read its annual report and announcements is Companies House and the London Stock Exchange RNS announcements — find-and-update.company-information.service.gov.uk.

No SEC filer could be matched to “Fulcrum metals plc bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Fulcrum metals plc”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “fulcrum” (search terms considered: fulcrum, metals).

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “fulcrum” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 100 entities whose registered name contains the word “fulcrum”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “fulcrum” 100, “metals” 474. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “fulcrum” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Gaslog partners lp bullish and bearish analyst opinions

For “Gaslog partners lp bullish and bearish analyst opinions”, the matching SEC registrant is GasLog Partners LP, which trades as GLOP-PA, GLOP-PB, GLOP-PC and files under Central Index Key 1598655. EDGAR puts it in the “Water Transportation” industry code with Marshall Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-23, across 365 filings on record. This is reference material, not trading advice.

Financial trend for GasLog Partners LP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $371.03 million (2022-12-31) to $278.22 million (2025-12-31), a change of -25.0%; net income (loss) went from $118.99 million (2022-12-31) to -$20.15 million (2025-12-31), a change of -116.9%; total assets went from $2.02 billion (2022-12-31) to $1.20 billion (2025-12-31), a change of -40.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1598655, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures GasLog Partners LP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on GasLog Partners LP (CIK 1598655) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 201 8-K or 6-K reports in GasLog Partners LP’s recent EDGAR index, the 4 listed here run from 2026-04-24 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 365 recent EDGAR filings, GasLog Partners LP most often filed 6-K (201), SC 13G/A (28), CORRESP (17), 424B2 (17). A selection from 2026-03-18 to 2026-03-19:

The full record for CIK 1598655 is on the EDGAR company page; the latest 20-F there is dated 2026-03-19 and the oldest filing in the recent index dates from 2014-02-03. Insider trades for GasLog Partners LP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gcm resources plc bullish and bearish analyst opinions

“plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. The name “Gcm resources plc” therefore points to a company organised in the United Kingdom, and its official disclosures are on Companies House and the London Stock Exchange RNS announcements (find-and-update.company-information.service.gov.uk), not on EDGAR.

No SEC filer could be matched to “Gcm resources plc bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Gcm resources plc” appears in 3 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “gcm” (search terms considered: gcm, resources).

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “gcm” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 3 most relevant full-text hits returned for “Gcm resources plc”, filings range from 2008-03-31 to 2008-08-26. The filers whose documents mention it most often are FIDELITY INVESTMENT TRUST (CIK 0000744822) (3 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 180 entities whose registered name contains the word “gcm”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “gcm” 180, “resources” 478. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “gcm” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Geovax labs, inc. bullish and bearish analyst opinions

For “Geovax labs, inc. bullish and bearish analyst opinions”, the matching SEC registrant is GeoVax Labs, Inc., which trades as GOVX and files under Central Index Key 832489. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was DAUPHIN TECHNOLOGY INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-09-23, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for GeoVax Labs, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $81,526 (2022-12-31) to $2.49 million (2025-12-31), a change of +2953.2%; net income (loss) went from -$14.02 million (2022-12-31) to -$21.46 million (2025-12-31), a change of -53.1%; total assets went from $31.35 million (2022-12-31) to $6.34 million (2025-12-31), a change of -79.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 832489, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures GeoVax Labs, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on GeoVax Labs, Inc. (CIK 832489) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-27, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 212 8-K or 6-K reports in GeoVax Labs, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-27 to 2026-09-10, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, GeoVax Labs, Inc. most often filed 4 (234), 8-K (212), 424B3 (103), 10-Q (55). A selection from 2026-08-14 to 2026-09-23:

The full record for CIK 832489 is on the EDGAR company page; the latest 10-K there is dated 2026-04-15 and the oldest filing in the recent index dates from 2008-06-23. Insider trades for GeoVax Labs, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gibo holdings limited bullish and bearish analyst opinions

For “Gibo holdings limited bullish and bearish analyst opinions”, the matching SEC registrant is GIBO HOLDINGS Ltd, which trades as GIBO, GIBOW and files under Central Index Key 2034520. EDGAR puts it in the “Services-Prepackaged Software” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-09-22, across 54 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-05-15 by GIBO HOLDINGS Ltd (CIK 2034520) — source document:

GIBO Holdings Limited is an exempted company incorporated under the laws of the Cayman Islands. We began our operations through Hong Kong Daily Group Supply Chain Limited (“HK Daily” or the “Hong Kong Subsidiary”), a limited liability company incorporated under the laws of Hong Kong in December 2017. We subsequently underwent a series of restructuring transactions, which primarily include: (i) in June 2023, Global IBO Group Ltd. (“GIBO”) was incorporated as an offshore holding company in the Cayman Islands; (ii) in September 2023, Global IBO AI Technology Ltd (“GIBO AI”), was established in the Cayman Islands as a wholly-owned subsidiary of GIBO; (iii) in November 2023, GIBO International Ltd was incorporated in Samoa as a wholly-owned subsidiary GIBO; and (iv) in December 2023, GIBO AI acquired 100% of the equity interests in HK Daily in December 2023.

Financial trend for GIBO HOLDINGS Ltd from annual reports, periods 2023-12-31 to 2025-12-31: revenue was tagged only for 2024-12-31 at $30.00 million; net income (loss) went from -$12.12 million (2023-12-31) to -$231.91 million (2025-12-31), a change of -1813.8%; total assets went from $112.80 million (2024-12-31) to $833,737 (2025-12-31), a change of -99.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2034520, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures GIBO HOLDINGS Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on GIBO HOLDINGS Ltd (CIK 2034520) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 12 8-K or 6-K reports in GIBO HOLDINGS Ltd’s recent EDGAR index, the 4 listed here run from 2026-03-09 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2034520 is on the EDGAR company page; the latest 20-F there is dated 2026-05-15 and the oldest filing in the recent index dates from 2024-09-12. Insider trades for GIBO HOLDINGS Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gogoro inc. bullish and bearish analyst opinions

For “Gogoro inc. bullish and bearish analyst opinions”, the matching SEC registrant is Gogoro Inc., which trades as GGR, GGROW and files under Central Index Key 1886190. EDGAR puts it in the “Motor Vehicles & Passenger Car Bodies” industry code with Taiwan as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-10-16, across 158 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-31 by Gogoro Inc. (CIK 1886190) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 42 A. Operating Results 42 B. Liquidity and Capital Resources 46 C. Research and Development, Patents and Licenses, etc. 49 D. Trend Information 49 E. Critical Accounting Estimates 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 51 A. Directors and Senior Management 51 B. Compensation of Directors and Executive Officers 52 C. Board Practices 57 D. Employees 59 E. Share Ownership 60 F. Disclosure of a registrant’s action to recover erroneously awarded compensation 61 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 61 A. Major Shareholders 61 B. Related Party Transactions 61 C . Interests of Experts and Counsel 62 ITEM 8. FINANCIAL INFORMATION 63 A. Consolidated Statements and Other Financial Information 63 B. Significant Changes 64 ITEM 9.

Financial trend for Gogoro Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$98.91 million (2022-12-31) to -$79.97 million (2025-12-31), a change of +19.1%; total assets went from $873.42 million (2022-12-31) to $601.57 million (2025-12-31), a change of -31.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1886190, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Gogoro Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Gogoro Inc. (CIK 1886190) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 49 8-K or 6-K reports in Gogoro Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-29 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1886190 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-11-05. Insider trades for Gogoro Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gpi s.p.a. bullish and bearish analyst opinions

The legal-form ending in “Gpi s.p.a.” is the clue: “S.p.A.” is the Italian joint-stock company form (società per azioni). A company of that kind reports in Italy, so the place to read its annual report and announcements is Borsa Italiana and CONSOB’s issuer disclosures — www.consob.it.

No SEC filer could be matched to “Gpi s.p.a. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Gpi s.p.a.” appears in 73 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “gpi” (search terms considered: gpi).

In the 73 most relevant full-text hits returned for “Gpi s.p.a.”, filings range from 2022-06-27 to 2026-09-24. The filers whose documents mention it most often are Dimensional ETF Trust (CIK 0001816125) (64 hits); John Hancock Funds II (CIK 0001331971) (5 hits); WisdomTree Trust (CIK 0001350487) (3 hits); Mediobanca - Banca di Credito Finanziario SpA (CIK 0001379481) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 92 entities whose registered name contains the word “gpi”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “gpi” 92. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “gpi” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Gsm foils ltd. bullish and bearish analyst opinions

Read from its name, “Gsm foils ltd.” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Gsm foils ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Gsm foils ltd.”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “gsm” (search terms considered: gsm, foils).

EDGAR’s company index has 12 entities whose registered name contains the word “gsm”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “gsm” 12, “foils” 2. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “gsm”: COOK INLET/VS GSM IV PCS HOLDINGS, LLC (CIK 1578080), FF GSM FUND 2 LLC (CIK 1972531), FLORIDA FUNDERS GSM FUND, LLC (CIK 1803726); containing “foils”: A.J. OSTER FOILS, LLC (CIK 1575079), HANOVER FOILS LLC (CIK 1473336). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “gsm” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Gyre therapeutics, inc. bullish and bearish analyst opinions

For “Gyre therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is GYRE THERAPEUTICS, INC., which trades as GYRE and files under Central Index Key 1124105. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was CATALYST BIOSCIENCES, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-13 by GYRE THERAPEUTICS, INC. (CIK 1124105) — source document:

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California. In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY® (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis. Fibrotic diseases affect large patient populations worldwide and involve complex, multi-stage biological processes driven by multiple molecular pathways. Given this complexity, therapies that modulate key profibrotic signaling pathways may offer meaningful clinical benefit; however, effective treatment may require targeting mechanisms across different stages of disease progression.

Financial trend for GYRE THERAPEUTICS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $4.31 million (2022-12-31) to $9.88 million (2025-12-31), a change of +129.0%; total assets went from $84.75 million (2022-12-31) to $166.13 million (2025-12-31), a change of +96.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1124105, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures GYRE THERAPEUTICS, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on GYRE THERAPEUTICS, INC. (CIK 1124105) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-07, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 212 8-K or 6-K reports in GYRE THERAPEUTICS, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-07 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1124105 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2013-09-10. Insider trades for GYRE THERAPEUTICS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hao wen holdings limited bullish and bearish analyst opinions

The legal-form ending in “Hao wen holdings limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Hao wen holdings limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Hao wen holdings limited” appears in 49 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “hao” (search terms considered: hao, wen).

A broader EDGAR full-text search for the shorter phrase “Hao wen holdings” finds 50 filing documents; among the top 50, the filers mentioning it most are Planet Green Holdings Corp. (PLAG) (CIK 0001117057) (21); Biostar Pharmaceuticals, Inc. (CIK 0001418133) (15); Chineseinvestors.com, Inc. (CIK 0001459482) (7). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 49 most relevant full-text hits returned for “Hao wen holdings limited”, filings range from 2011-04-12 to 2026-09-28. The filers whose documents mention it most often are Planet Green Holdings Corp. (PLAG) (CIK 0001117057) (21 hits); Biostar Pharmaceuticals, Inc. (CIK 0001418133) (14 hits); Chineseinvestors.com, Inc. (CIK 0001459482) (7 hits); China Power Equipment, Inc. (CIK 0001418134) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 72 entities whose registered name contains the word “hao”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “hao” 72, “wen” 115. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “hao” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Hawthorn bancshares, inc. bullish and bearish analyst opinions

For “Hawthorn bancshares, inc. bullish and bearish analyst opinions”, the matching SEC registrant is HAWTHORN BANCSHARES, INC., which trades as HWBK and files under Central Index Key 893847. EDGAR puts it in the “National Commercial Banks” industry code with MO as its state or country of incorporation; its earlier registered name was EXCHANGE NATIONAL BANCSHARES INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-10, across 919 filings on record. This is reference material, not trading advice.

Financial trend for HAWTHORN BANCSHARES, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $69.26 million (2022-12-31) to $97.66 million (2025-12-31), a change of +41.0%; net income (loss) went from $20.75 million (2022-12-31) to $23.80 million (2025-12-31), a change of +14.7%; total assets went from $1.92 billion (2022-12-31) to $1.89 billion (2025-12-31), a change of -1.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 893847, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 4 periods shown, dashes mark figures HAWTHORN BANCSHARES, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HAWTHORN BANCSHARES, INC. (CIK 893847) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 243 8-K or 6-K reports in HAWTHORN BANCSHARES, INC.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-09-10, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 919 recent EDGAR filings, HAWTHORN BANCSHARES, INC. most often filed 8-K (243), 4 (221), 5 (131), 10-Q (86). A selection from 2026-07-17 to 2026-08-28:

The full record for CIK 893847 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 1996-08-02. Insider trades for HAWTHORN BANCSHARES, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Helix exploration plc bullish and bearish analyst opinions

“plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. The name “Helix exploration plc” therefore points to a company organised in the United Kingdom, and its official disclosures are on Companies House and the London Stock Exchange RNS announcements (find-and-update.company-information.service.gov.uk), not on EDGAR.

No SEC filer could be matched to “Helix exploration plc bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Helix exploration plc”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “helix” (search terms considered: helix, exploration).

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “helix” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

Word by word, the number of EDGAR registrant names containing each term of this search is: “helix” 83, “exploration” 483. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “helix” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Henry boot plc bullish and bearish analyst opinions

The legal-form ending in “Henry boot plc” is the clue: “plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. A company of that kind reports in the United Kingdom, so the place to read its annual report and announcements is Companies House and the London Stock Exchange RNS announcements — find-and-update.company-information.service.gov.uk.

No SEC filer could be matched to “Henry boot plc bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Henry boot plc” appears in 4859+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “henry” (search terms considered: henry, boot).

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “henry” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Henry boot plc”, filings range from 2006-03-30 to 2026-09-24. The filers whose documents mention it most often are FIDELITY PURITAN TRUST (CIK 0000081205) (32 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (28 hits); WisdomTree Trust (CIK 0001350487) (17 hits); HOTCHKIS & WILEY FUNDS /DE/ (CIK 0001145022) (11 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 197+ entities whose registered name contains the word “henry”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “henry” 491, “boot” 11. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “henry” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Heron therapeutics, inc. bullish and bearish analyst opinions

For “Heron therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is HERON THERAPEUTICS, INC. /DE/, which trades as HRTX and files under Central Index Key 818033. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was AP PHARMA INC /DE/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-21, across 1001 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by HERON THERAPEUTICS, INC. /DE/ (CIK 818033) — source document:

We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients. Acute Care Product Portfolio ZYNRELEF ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only modified-release local anesthetic to be classified by the FDA as an extended-release product because ZYNRELEF demonstrated in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control.

Financial trend for HERON THERAPEUTICS, INC. /DE/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $107.67 million (2022-12-31) to $154.90 million (2025-12-31), a change of +43.9%; net income (loss) went from -$182.02 million (2022-12-31) to -$20.20 million (2025-12-31), a change of +88.9%; total assets went from $250.95 million (2022-12-31) to $255.88 million (2025-12-31), a change of +2.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 818033, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures HERON THERAPEUTICS, INC. /DE/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HERON THERAPEUTICS, INC. /DE/ (CIK 818033) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 242 8-K or 6-K reports in HERON THERAPEUTICS, INC. /DE/’s recent EDGAR index, the 4 listed here run from 2026-06-25 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 818033 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2011-05-18. Insider trades for HERON THERAPEUTICS, INC. /DE/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hirequest, inc. bullish and bearish analyst opinions

For “Hirequest, inc. bullish and bearish analyst opinions”, the matching SEC registrant is HireQuest, Inc., which trades as HQI and files under Central Index Key 1140102. EDGAR puts it in the “Services-Help Supply Services” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Command Center, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-14, across 904 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by HireQuest, Inc. (CIK 1140102) — source document:

Development of our Business HireQuest, Inc. (collectively with its subsidiaries, the “Company,” “we,” “us,” or “our”) is a Delaware corporation originally organized in Washington as Command Staffing, LLC in 2002. In 2005, Temporary Financial Services, Inc., a public company, acquired the assets of Command Staffing, LLC, and the combined entity changed its name to Command Center, Inc. On September 11, 2019, Command Center, Inc. reincorporated in Delaware and changed its name to HireQuest, Inc. following its acquisition of Hire Quest Holdings, LLC (“Hire Quest Holdings,” and together with its subsidiary, Hire Quest, LLC, “Legacy HQ”). This acquisition is sometimes referred to as the “Merger.” Hire Quest, LLC was formed as a Florida limited liability company in 2002.

Financial trend for HireQuest, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $30.95 million (2022-12-31) to $30.64 million (2025-12-31), a change of -1.0%; net income (loss) went from $12.46 million (2022-12-31) to $6.33 million (2025-12-31), a change of -49.2%; total assets went from $103.28 million (2022-12-31) to $88.23 million (2025-12-31), a change of -14.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1140102, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures HireQuest, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HireQuest, Inc. (CIK 1140102) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 192 8-K or 6-K reports in HireQuest, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1140102 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2001-05-07. Insider trades for HireQuest, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Horace mann educators corporation bullish and bearish analyst opinions

For “Horace mann educators corporation bullish and bearish analyst opinions”, the matching SEC registrant is HORACE MANN EDUCATORS CORP /DE/, which trades as HMN and files under Central Index Key 850141. EDGAR puts it in the “Fire, Marine & Casualty Insurance” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for HORACE MANN EDUCATORS CORP /DE/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.38 billion (2022-12-31) to $1.70 billion (2025-12-31), a change of +23.1%; net income (loss) went from $19.80 million (2022-12-31) to $162.10 million (2025-12-31), a change of +718.7%; total assets went from $13.31 billion (2022-12-31) to $15.27 billion (2025-12-31), a change of +14.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 850141, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures HORACE MANN EDUCATORS CORP /DE/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HORACE MANN EDUCATORS CORP /DE/ (CIK 850141) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 131 8-K or 6-K reports in HORACE MANN EDUCATORS CORP /DE/’s recent EDGAR index, the 4 listed here run from 2026-07-21 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 850141 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2011-10-26. Insider trades for HORACE MANN EDUCATORS CORP /DE/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hovnanian enterprises, inc. bullish and bearish analyst opinions

For “Hovnanian enterprises, inc. bullish and bearish analyst opinions”, the matching SEC registrant is HOVNANIAN ENTERPRISES INC, which trades as HOV, HOVVB, HOVNP and files under Central Index Key 357294. EDGAR puts it in the “Operative Builders” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-28, across 1005 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-22 by HOVNANIAN ENTERPRISES INC (CIK 357294) — source document:

Hovnanian Enterprises, Inc. (“HEI”) conducts all of its homebuilding and financial services operations through its subsidiaries (references herein to the “Company,” “we,” “us” or “our” refer to HEI and its consolidated subsidiaries and should be understood to reflect the consolidated business of HEI’s subsidiaries). Through its subsidiaries, HEI designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments and is one of the nation’s largest builders of residential homes. Founded in 1959 by Kevork Hovnanian, HEI was incorporated in New Jersey in 1967 and reincorporated in Delaware in 1983 . Since the incorporation of HEI’s predecessor company, the Company combined with its unconsolidated joint ventures have delivered in excess of 382,000 homes, including 6,431 homes in fiscal 2025 . The Company has two distinct operations: homebuilding and financial services.

Financial trend for HOVNANIAN ENTERPRISES INC from annual reports, periods 2022-10-31 to 2025-10-31: revenue went from $2.92 billion (2022-10-31) to $2.98 billion (2025-10-31), a change of +1.9%; total assets went from $2.56 billion (2022-10-31) to $2.63 billion (2025-10-31), a change of +2.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 357294, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures HOVNANIAN ENTERPRISES INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HOVNANIAN ENTERPRISES INC (CIK 357294) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-20, and the most recent 10-K annual report was filed 2025-12-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 179 8-K or 6-K reports in HOVNANIAN ENTERPRISES INC’s recent EDGAR index, the 4 listed here run from 2026-02-25 to 2026-08-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 357294 is on the EDGAR company page; the latest 10-K there is dated 2025-12-22 and the oldest filing in the recent index dates from 2010-06-14. Insider trades for HOVNANIAN ENTERPRISES INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Huadi international group co., ltd. bullish and bearish analyst opinions

For “Huadi international group co., ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Huadi International Group Co., Ltd., which trades as HUDI and files under Central Index Key 1791725. EDGAR puts it in the “Steel Pipe & Tubes” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-08-19, across 100 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-01-30 by Huadi International Group Co., Ltd. (CIK 1791725) — source document:

Huadi International was incorporated in the Cayman Islands with limited liability on September 27, 2018. Huadi International does not have any operations, and it conducts business through its subsidiaries in China. Our PRC operating entities, Huadi Steel and Huadi Songyang, were established in 1998 and 2023, respectively, in China. Our main business operation focuses on new product development, manufacturing, marketing, and sales of stainless steel seamless pipes, tubes, and stainless steel bars. We also supply products for use in the thermal and nuclear power plants, automotive, oil and gas, agricultural and industrial equipment, chemical engineering, and electricity markets. We manufacture many of our products to operate under specialized conditions, including in load-bearing, high-pressure, corrosive and high-temperature environments.

Financial trend for Huadi International Group Co., Ltd. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $1.66 million (2022-09-30) to $1.22 million (2023-09-30), a change of -26.7%; net income (loss) went from $1.92 million (2022-09-30) to -$1.40 million (2025-09-30), a change of -172.5%; total assets went from $84.64 million (2022-09-30) to $109.52 million (2025-09-30), a change of +29.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1791725, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Huadi International Group Co., Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Huadi International Group Co., Ltd. (CIK 1791725) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-01-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 28 8-K or 6-K reports in Huadi International Group Co., Ltd.’s recent EDGAR index, the 4 listed here run from 2024-08-06 to 2026-07-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1791725 is on the EDGAR company page; the latest 20-F there is dated 2026-01-30 and the oldest filing in the recent index dates from 2019-11-04. Insider trades for Huadi International Group Co., Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Humana ab (publ) bullish and bearish analyst opinions

The legal-form ending in “Humana ab (publ)” is the clue: “AB (publ)” marks a Swedish public limited company (aktiebolag) allowed to offer shares to the public. A company of that kind reports in Sweden, so the place to read its annual report and announcements is Nasdaq Stockholm / Spotlight announcements and the Swedish FSA (Finansinspektionen) register — www.fi.se.

No SEC filer could be matched to “Humana ab (publ) bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Humana ab publ”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “humana” (search terms considered: humana).

A broader EDGAR full-text search for the shorter phrase “Humana ab” finds 5226+ filing documents; among the top 100, the filers mentioning it most are HARBOR FUNDS (CIK 0000793769) (17); FORUM FUNDS II (CIK 0001576367) (11); iSHARES TRUST (CIK 0001100663) (11). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Sweden. Companies there file with Nasdaq Stockholm and Finansinspektionen rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “humana” is therefore the Sweden regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 4 entities whose registered name contains the word “humana”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “humana” 4. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “humana” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Icecure medical ltd bullish and bearish analyst opinions

For “Icecure medical ltd bullish and bearish analyst opinions”, the matching SEC registrant is IceCure Medical Ltd., which trades as ICCM and files under Central Index Key 1584371. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13, across 315 filings on record. This is reference material, not trading advice.

Financial trend for IceCure Medical Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $3.08 million (2022-12-31) to $3.38 million (2025-12-31), a change of +9.5%; net income (loss) went from -$16.98 million (2022-12-31) to -$15.06 million (2025-12-31), a change of +11.3%; total assets went from $30.19 million (2022-12-31) to $13.89 million (2025-12-31), a change of -54.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1584371, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures IceCure Medical Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on IceCure Medical Ltd. (CIK 1584371) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 176 8-K or 6-K reports in IceCure Medical Ltd.’s recent EDGAR index, the 4 listed here run from 2026-09-28 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 315 recent EDGAR filings, IceCure Medical Ltd. most often filed 6-K (176), EFFECT (16), 3 (14), UPLOAD (12). A selection from 2026-08-17 to 2026-08-18:

The full record for CIK 1584371 is on the EDGAR company page; the latest 20-F there is dated 2026-03-17 and the oldest filing in the recent index dates from 2013-09-12. Insider trades for IceCure Medical Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Immunic, inc. bullish and bearish analyst opinions

For “Immunic, inc. bullish and bearish analyst opinions”, the matching SEC registrant is IMMUNIC, INC., which trades as IMUX and files under Central Index Key 1280776. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was VITAL THERAPIES INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-10-01, across 830 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by IMMUNIC, INC. (CIK 1280776) — source document:

Immunic, Inc. (“Immunic," “we,” “us,” “our” or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany. We had 92 employees as of February 1, 2026. We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases.

Financial trend for IMMUNIC, INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$120.41 million (2022-12-31) to -$97.17 million (2025-12-31), a change of +19.3%; total assets went from $127.75 million (2022-12-31) to $24.05 million (2025-12-31), a change of -81.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1280776, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures IMMUNIC, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on IMMUNIC, INC. (CIK 1280776) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 177 8-K or 6-K reports in IMMUNIC, INC.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-09-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1280776 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-22 and the oldest filing in the recent index dates from 2004-02-18. Insider trades for IMMUNIC, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Immunocore holdings plc bullish and bearish analyst opinions

For “Immunocore holdings plc bullish and bearish analyst opinions”, the matching SEC registrant is Immunocore Holdings plc, which trades as IMCR and files under Central Index Key 1671927. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with United Kingdom as its state or country of incorporation; its earlier registered name was Immunocore Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-07, across 279 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-25 by Immunocore Holdings plc (CIK 1671927) — source document:

We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX ® ( I mmune m obilizing m onoclonal T CRs A gainst X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas. In 2022, we received approval for our lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma ("mUM") from the FDA, the European Commission and other health authorities.

Financial trend for Immunocore Holdings plc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $174.36 million (2022-12-31) to $249.43 million (2023-12-31), a change of +43.1%; net income (loss) went from -$52.54 million (2022-12-31) to -$35.51 million (2025-12-31), a change of +32.4%; total assets went from $526.76 million (2022-12-31) to $1.07 billion (2025-12-31), a change of +102.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1671927, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Immunocore Holdings plc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Immunocore Holdings plc (CIK 1671927) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 73 8-K or 6-K reports in Immunocore Holdings plc’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1671927 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2016-04-13. Insider trades for Immunocore Holdings plc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Incannex healthcare limited bullish and bearish analyst opinions

For “Incannex healthcare limited bullish and bearish analyst opinions”, the matching SEC registrant is Incannex Healthcare Inc., which trades as IXHL and files under Central Index Key 1873875. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Incannex Healthcare Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-K filed 2026-09-25, across 263 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-09-25 by Incannex Healthcare Inc. (CIK 1873875) — source document:

We are a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. Our principal development priority is IHL-42X for obstructive sleep apnea. We are also evaluating the next clinical development plan for PSX-001 in generalized anxiety disorder and the potential for further development of IHL-675A in inflammatory conditions. Our aim is to offer patients additional treatment options where existing care does not adequately meet their needs. IHL-42X, our lead drug candidate for the treatment of obstructive sleep apnea (“OSA”), is an oral fixed-dose combination of dronabinol and acetazolamide designed to act synergistically by targeting two different physiological pathways associated with the intermittent hypoxia and hypercapnia that characterize OSA. We completed the Phase 2 portion of our RePOSA Phase 2/3 clinical trial (the "RePOSA Study") in July 2025, in which we observed that IHL-42X reduced apnea hypopnea index (“AHI”), improved patient reported outcome measures and was well-tolerated in OSA patients.

Financial trend for Incannex Healthcare Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue was tagged only for 2024-06-30 at $12,000; net income (loss) went from -$48.81 million (2023-06-30) to -$19.30 million (2026-06-30), a change of +60.5%; total assets went from $23.78 million (2023-06-30) to $72.98 million (2026-06-30), a change of +206.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1873875, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Incannex Healthcare Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Incannex Healthcare Inc. (CIK 1873875) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-09-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 151 8-K or 6-K reports in Incannex Healthcare Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1873875 is on the EDGAR company page; the latest 10-K there is dated 2026-09-25 and the oldest filing in the recent index dates from 2021-08-17. Insider trades for Incannex Healthcare Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Indaptus therapeutics, inc. bullish and bearish analyst opinions

For “Indaptus therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Indaptus Therapeutics, Inc., which trades as INDP and files under Central Index Key 1857044. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Intec Parent Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13D/A filed 2026-10-22, across 343 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-17 by Indaptus Therapeutics, Inc. (CIK 1857044) — source document:

We are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity in preclinical models, including durable anti-tumor response synergy observed with each of four different classes of existing agents, including NSAIDs, checkpoint therapy, targeted antibody therapy and low-dose chemotherapy.

Financial trend for Indaptus Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$14.32 million (2022-12-31) to -$20.85 million (2025-12-31), a change of -45.6%; total assets went from $28.06 million (2022-12-31) to $9.31 million (2025-12-31), a change of -66.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1857044, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Indaptus Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Indaptus Therapeutics, Inc. (CIK 1857044) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 74 8-K or 6-K reports in Indaptus Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-04 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1857044 is on the EDGAR company page; the latest 10-K there is dated 2026-03-17 and the oldest filing in the recent index dates from 2021-04-20. Insider trades for Indaptus Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Inlif limited bullish and bearish analyst opinions

For “Inlif limited bullish and bearish analyst opinions”, the matching SEC registrant is INLIF Ltd, which trades as INLF and files under Central Index Key 1991592. EDGAR puts it in the “General Industrial Machinery & Equipment, NEC” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-22, across 96 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-06 by INLIF Ltd (CIK 1991592) — source document:

INLIF Cayman was incorporated on January 4, 2023, as an exempted company with limited liability in the Cayman Islands. On January 30, 2023, Yunfei BVI was incorporated in the British Virgin Islands as a business company with limited liability and a wholly owned subsidiary of INLIF Cayman. On March 8, 2023, Juli HK was incorporated in Hong Kong as a limited company and a wholly-owned subsidiary of Yunfei BVI. On April 21, 2023, Fujian INLIF was incorporated in the PRC as a PRC limited liability company and a wholly-owned subsidiary of Juli HK. Ewatt is a PRC limited liability company established on September 28, 2016, 94% of the equity interests of which is owned by Fujian INLIF after the First Reorganization and the Second Reorganization (each as defined below).

Financial trend for INLIF Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $6.65 million (2022-12-31) to $18.41 million (2025-12-31), a change of +176.7%; net income (loss) went from $537,555 (2022-12-31) to -$5.45 million (2025-12-31), a change of -1113.2%; total assets went from $16.02 million (2023-12-31) to $24.78 million (2025-12-31), a change of +54.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1991592, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures INLIF Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on INLIF Ltd (CIK 1991592) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 26 8-K or 6-K reports in INLIF Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1991592 is on the EDGAR company page; the latest 20-F there is dated 2026-03-06 and the oldest filing in the recent index dates from 2023-11-06. Insider trades for INLIF Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Inno laser technology co., ltd. bullish and bearish analyst opinions

Read from its name, “Inno laser technology co., ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Inno laser technology co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Inno laser technology co., ltd.”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “inno” (search terms considered: inno, laser, technology).

Even the shorter phrase “Inno laser technology” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (inno, laser, technology) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 4 entities whose registered name contains the word “inno”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “inno” 4, “laser” 97, “technology” 485. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “inno”: AIRX INNO FUND LIMITED PARTNERSHIP (CIK 1783966), INNO GLOBAL TECHNOLOGY LTD (CIK 1427105), INNO HOLDINGS INC. (CIK 1961847); containing “laser”: ADVANCED LASER HEALTH CORP (CIK 1183749), AESTHETIC LASER RENTALS LLC (CIK 1925688), AIRMED LASER INC. (CIK 1628913); containing “technology”: 100 TECHNOLOGY LLC (CIK 1827627), 102 TECHNOLOGY LLC (CIK 1310921), 128 TECHNOLOGY, INC. (CIK 1627997). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “inno” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Innoviva, inc. bullish and bearish analyst opinions

For “Innoviva, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Innoviva, Inc., which trades as INVA and files under Central Index Key 1080014. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was THERAVANCE INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-24, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-25 by Innoviva, Inc. (CIK 1080014) — source document:

Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR ® /BREO ® ELLIPTA ® (fluticasone furoate/vilanterol, “FF/VI”) and ANORO ® ELLIPTA ® (umeclidinium bromide/vilanterol, “UMEC/VI”). Under the Long-Acting Beta-2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO ® ELLIPTA ® , which tier upward at a range from 6.5% to 10%.

Financial trend for Innoviva, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $220.26 million (2022-12-31) to $271.17 million (2025-12-31), a change of +23.1%; total assets went from $1.23 billion (2022-12-31) to $1.64 billion (2025-12-31), a change of +32.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1080014, tags Assets, ProfitLoss, Revenues; 4 periods shown, dashes mark figures Innoviva, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Innoviva, Inc. (CIK 1080014) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 266 8-K or 6-K reports in Innoviva, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-04 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1080014 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-27 and the oldest filing in the recent index dates from 2012-11-20. Insider trades for Innoviva, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Inuvo, inc. bullish and bearish analyst opinions

For “Inuvo, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Inuvo, Inc., which trades as INUV and files under Central Index Key 829323. EDGAR puts it in the “Services-Advertising” industry code with NV as its state or country of incorporation; its earlier registered name was KOWABUNGA! INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-05 by Inuvo, Inc. (CIK 829323) — source document:

Inuvo is a market leader in generative artificial intelligence for modeling media audiences. As a leading provider of AI-driven data and advertising technology solutions, we have successfully commercialized a proprietary, patented large language model (“LLM”) that identifies and actions the reasons why consumers are interested in products, services, or brands - rather than who they are - offering a high-performance, privacy-by-design solution for the modern advertising landscape. Intelligence for the Agentic Era. As the industry moves toward “agentic” systems - where autonomous AI agents increasingly handle the planning and execution of media tasks - Inuvo is uniquely positioned as a critical intelligence layer. Unlike legacy systems that rely on static historical data or consumer IDs (cookies), Inuvo’s technology provides the real-time, intent-based reasoning required for autonomous media planning and activation.

Financial trend for Inuvo, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $83.79 million (2024-12-31) to $86.21 million (2025-12-31), a change of +2.9%; net income (loss) went from -$13.11 million (2022-12-31) to -$5.10 million (2025-12-31), a change of +61.1%; total assets went from $35.56 million (2022-12-31) to $24.87 million (2025-12-31), a change of -30.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 829323, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Inuvo, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Inuvo, Inc. (CIK 829323) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 272 8-K or 6-K reports in Inuvo, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-23 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 829323 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2010-12-13. Insider trades for Inuvo, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Iqstel inc. bullish and bearish analyst opinions

For “Iqstel inc. bullish and bearish analyst opinions”, the matching SEC registrant is iQSTEL Inc, which trades as IQST and files under Central Index Key 1527702. EDGAR puts it in the “Telephone Communications (No Radiotelephone)” industry code with NV as its state or country of incorporation; its earlier registered name was PURESNAX INTERNATIONAL, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-28, across 419 filings on record. This is reference material, not trading advice.

Financial trend for iQSTEL Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $93.20 million (2022-12-31) to $316.90 million (2025-12-31), a change of +240.0%; net income (loss) went from -$5.97 million (2022-12-31) to -$8.51 million (2025-12-31), a change of -42.6%; total assets went from $12.55 million (2022-12-31) to $51.09 million (2025-12-31), a change of +307.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1527702, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures iQSTEL Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on iQSTEL Inc (CIK 1527702) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-16, and the most recent 10-K annual report was filed 2026-04-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 183 8-K or 6-K reports in iQSTEL Inc’s recent EDGAR index, the 4 listed here run from 2026-07-10 to 2026-09-28, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 419 recent EDGAR filings, iQSTEL Inc most often filed 8-K (183), 10-Q (42), UPLOAD (31), CORRESP (30). A selection from 2026-07-10 to 2026-08-20:

The full record for CIK 1527702 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-23 and the oldest filing in the recent index dates from 2011-08-18. Insider trades for iQSTEL Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ispire technology inc. bullish and bearish analyst opinions

For “Ispire technology inc. bullish and bearish analyst opinions”, the matching SEC registrant is Ispire Technology Inc., which trades as ISPR and files under Central Index Key 1948455. EDGAR puts it in the “Cigarettes” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-23, across 176 filings on record. This is reference material, not trading advice.

Financial trend for Ispire Technology Inc. from annual reports, periods 2024-03-31 to 2026-06-30: revenue went from $151.91 million (2024-06-30) to $96.01 million (2026-06-30), a change of -36.8%; net income (loss) went from -$14.77 million (2024-06-30) to -$33.20 million (2026-06-30), a change of -124.8%; total assets went from $107.98 million (2024-03-31) to $64.28 million (2026-06-30), a change of -40.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1948455, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Ispire Technology Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ispire Technology Inc. (CIK 1948455) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-17, and the most recent 10-K annual report was filed 2026-09-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 42 8-K or 6-K reports in Ispire Technology Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-17 to 2026-09-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 176 recent EDGAR filings, Ispire Technology Inc. most often filed 8-K (42), 4 (41), CORRESP (15), 3 (14). A selection from 2026-05-12 to 2026-09-15:

The full record for CIK 1948455 is on the EDGAR company page; the latest 10-K there is dated 2026-09-15 and the oldest filing in the recent index dates from 2022-10-11. Insider trades for Ispire Technology Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Itonic holdings ltd. bullish and bearish analyst opinions

For “Itonic holdings ltd. bullish and bearish analyst opinions”, the matching SEC registrant is iTonic Holdings Ltd, which trades as ITOC and files under Central Index Key 1970544. EDGAR puts it in the “Electromedical & Electrotherapeutic Apparatus” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Pheton Holdings Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-02, across 84 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-30 by iTonic Holdings Ltd (CIK 1970544) — source document:

We are a Cayman Islands holding company and primarily conduct our operations in China through Beijing Feitian, a limited liability company formed in the PRC in 1998. Beijing Feitian is a healthcare solution provider dedicated to the development and commercialization of TPS for brachytherapy. Through Beijing Feitian, we are committed to leveraging our products and services to establish a potential new standard of care across multiple malignant tumor applications. In connection with the initial public offering, we underwent a series of restructuring of our corporate structure, which primarily included: ● On November 2, 2022, we incorporated Pheton, our holding company, as an exempted company with limited liability under the laws of the Cayman Islands. ● On November 22, 2022, Pheton BVI was incorporated in the BVI as a business company with limited liability, which is a wholly owned subsidiary of our Company. ● On December 14, 2022, we incorporated Pheton HK in Hong Kong as a wholly owned subsidiary of Pheton BVI. ● On March 15, 2023, we incorporated Jinruixi, our onshore holding company, as a wholly owned subsidiary of Pheton HK.

Financial trend for iTonic Holdings Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $679,777 (2022-12-31) to $523,031 (2025-12-31), a change of -23.1%; net income (loss) went from $83,980 (2022-12-31) to -$5.10 million (2025-12-31), a change of -6170.4%; total assets went from $1.62 million (2023-12-31) to $9.10 million (2025-12-31), a change of +462.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1970544, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures iTonic Holdings Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on iTonic Holdings Ltd (CIK 1970544) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 25 8-K or 6-K reports in iTonic Holdings Ltd’s recent EDGAR index, the 4 listed here run from 2026-08-27 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1970544 is on the EDGAR company page; the latest 20-F there is dated 2026-03-30 and the oldest filing in the recent index dates from 2023-06-02. Insider trades for iTonic Holdings Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jianzhi education technology group company limited bullish and bearish analyst opinions

For “Jianzhi education technology group company limited bullish and bearish analyst opinions”, the matching SEC registrant is Jianzhi Education Technology Group Co Ltd, which trades as JZ and files under Central Index Key 1852440. EDGAR puts it in the “Services-Educational Services” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Jianzhi Education Technology Group. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-09-01 (this view begins at filings dated on or before 2026-01-26), across 113 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-13 by Jianzhi Education Technology Group Co Ltd (CIK 1852440) (passage 2, continuing from the earlier excerpt) — source document:

In October 2016, Shanghai Ang’you Internet Technology Co., Ltd., or Shanghai Ang’you, became a 51.2% owned subsidiary of Beijing Sentu. To further expand the business operations, in October 2017, Beijing Sentu acquired 51% equity interests of Guangzhou Xingzhiqiao Information Technology Co., Ltd., or Guangzhou Xingzhiqiao, and in August 2018, acquired the remaining 49% equity interests of Guangzhou Xingzhiqiao. 54 In March 2018, Jianzhi Education Technology Group Company Limited was incorporated in the Cayman Islands as an exempted company with limited liability. In March 2018, Jianzhi Education Group Company Limited, or Jianzhi Education (BVI), was incorporated as a wholly-owned subsidiary of Jianzhi Education Technology Group Company Limited. In April 2018, Jianzhi Education Technology (HK) Company Limited, or Jianzhi Education (HK), was incorporated, and was held by Jianzhi Education (BVI) as an investment holding company.

Financial trend for Jianzhi Education Technology Group Co Ltd from annual reports, periods 2020-12-31 to 2021-12-31: revenue went from 404,931,954 CNY (2020-12-31) to 473,247,283 CNY (2021-12-31), a change of +16.9%; net income (loss) went from 82,323,899 CNY (2020-12-31) to 48,258,269 CNY (2021-12-31), a change of -41.4%; total assets was tagged only for 2021-12-31 at 859,617,155 CNY. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1852440, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures Jianzhi Education Technology Group Co Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Jianzhi Education Technology Group Co Ltd (CIK 1852440) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 29 8-K or 6-K reports in Jianzhi Education Technology Group Co Ltd’s recent EDGAR index, the 4 listed here run from 2026-01-26 to 2026-06-03, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1852440 is on the EDGAR company page; the latest 20-F there is dated 2026-04-13 and the oldest filing in the recent index dates from 2021-03-26. One example from this record is the 6-K filed 2026-07-01 (document). Insider trades for Jianzhi Education Technology Group Co Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET